MRKMerck Sharp & Dohme LLCSigning up patients
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Non Small Cell Lung Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 780 (planned)
- Started
- Apr 3, 2024
- Main results expected
- Feb 21, 2034
- Fully finished
- Oct 23, 2034
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Disease-free survival (DFS) as assessed by Blinded Independent Central Review (BICR)
Measured over: Up to ~ 93 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06312137 · record last updated 2026-10-15 · checked 2026-11-09 15:47 UTC